ELEMENTS OF ORPHAN DRUGS VALUE
Author(s)
Korchagina D1, Millier A2, Toumi M3, Falissard B4
1University of Paris-Sud, Paris, France, 2Creativ-Ceutical, Paris, France, 3Aix-Marseille University, Marseille, France, 4Maison de Solenn, Paris, France
OBJECTIVES: Evaluation and pricing of orphan drugs (ODs) is a complex issue involving ethic and fairness aspects. The relevance of the current health technology assessment (HTA) approach relying of the cost-effectiveness was put into question in case of ODs assessment. Many authors support the idea of integrating multiple parameters when evaluating the value of ODs. The objective of the study was to identify the criteria (elements of value) that should be included in the value assessment according to the published literature. METHODS: A systematic literature search was conducted in Medline database. Search strategy targeted all publications on the HTA methods for ODs and their social value. All articles that presented the analysis of HTA outcomes or access to ODs in different geographies, as well as drug/disease specific studies were excluded. The elements of value were extracted such as they were given by authors and categorised. RESULTS: The search was conducted in May 2016. Total of 811 articles were identified from Medline database and 19 were selected for the further analysis after abstract and full text screening. The elements of value were classified in the following categories: (1) disease specific including indication, unmet needs, impact on patient and caregiver (prognosis, QoL, social, etc.), population size, (2) product specific including efficacy profile (impact on survival, QoL, morbidity, response rate, etc.), safety profile, innovation profile, manufacturing complexity, impact on public health and healthcare system, condition of use and treatment regimen, (3) uncertainty and quality of evidence, (4) economic including cost-effectiveness, budget impact, cost per patient, etc., (5) ethic, (6) external influence including political climate and patient associations/media pressure. CONCLUSIONS: There exists no tailored method for OD assessment. It is important to integrate multiple element of value in the assessment process. Multi-criteria decision analysis seems to be the most optimal method for OD assessment.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PSY146
Topic
Health Policy & Regulatory, Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes, Reimbursement & Access Policy
Disease
Rare and Orphan Diseases